Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial
Clinical trial NCT07248696 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07248696
- Sponsor
- Chongqing University Cancer Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-04
- Primary completion
- 2029-06-30
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.